Oern joined the OrganOx board as Non-Executive Chairman in December 2020. Oern has a wealth of experience in the Health Tech sector and over the past 10 years he has focused his attention on developing and steering companies in this sector to realise their full potential.

Prior to this, Oern spent 12 years at Medtronic in different positions including SVP & President, where he led a successful transformation of their global cardiac surgery business. He also spent 6 years in senior management positions at Abbott Laboratories Inc.

Before joining the Life Science industry, Oern trained and worked as a physician in Oslo.

Peter is OrganOx Co-Founder and Chief Medical Officer, and has worked with Constantin and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Peter leads OrganOx's pre-clinical and clinical programmes of OrganOx's patented normothermic organ perfusion technology.

Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes. Earlier in his career Peter was Clinical Director of the Transplant Centre at Addenbrooke’s Hospital, Cambridge, one of the UK’s leading liver transplant centres and visiting Assistant Professor of Surgery at Indiana University Medical Centre, USA, where he established their liver transplant programme.

Peter's research interests lie primarily in novel applications of normothermic organ perfusion, ranging from its use for extracorporeal support to preservation and repair prior to transplantation. He has published over 25 papers on the topic of normothermic perfusion, the basis of the OrganOx technology, as well as in the areas of clinical transplantation, immunosuppression, monoclonal antibodies, xenotransplantation, liver perfusion and aspects of general surgery.

Constantin is OrganOx Co-Founder and Chief Technical Officer and has worked with Peter and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Constantin leads OrganOx's technical development programmes.

Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. Constantin founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).

Constantin's research interests include normothermic organ perfusion, drug delivery, acoustic cavitation and therapeutic ultrasound. Constantin received the 2017 Royal Academy of Engineering Silver Medal and was appointed as a Fellow of the Royal Academy of Engineering in 2019.

Craig joined OrganOx in December 2016. In January 2017 he transitioned to the role of CEO, leading the company’s efforts to advance organ technology to make every organ count.

Prior to joining the company, Craig served as managing director at Siemens Magnet Technology and simultaneously held a role as an executive member of the Siemens Healthcare MRI business between 2010 and 2016. While at Siemens Magnet Technology, Craig applied his expertise in production and research and development to the development of a revolutionary new magnet contained within the World's strongest clinical MRI system, the Siemens MRI 7 Tesla product, MAGNETOM Terra. In addition, he previously held positions at Oxford Instruments, Amersham Plc and GE Healthcare in a variety of management and leadership roles within the in vivo diagnostics sector.

Craig holds an MBA from the University of Warwick Business School and a Bachelor’s of Engineering in Medical Engineering from the University of Liverpool.

Matthew joined the OrganOx board as a Non-Executive Director in 2009, when the company spun-out from the University of Oxford. Matthew has over twenty years of experience as a venture investor, focusing on highly disruptive healthcare, medtech and life science opportunities. In addition to OrganOx, he sits on other boards including Caristo Diagnostics, OxSonics, Momentum BioSciences, BioFidelity and Lightcast Discovery.

Matthew has a D.Phil (Biochemistry) from Oxford. After a brief research career, he began investing in early stage companies through Oxford Technology Management, before co-founding Longwall Venture Partners. Longwall has raised three funds over the last decade, and invests in early stage, UK-based science, engineering and healthcare businesses

Tim joined the OrganOx board as a Non-Executive Director in January 2020 following the investment by BGF. Tim has been active in the venture capital and start-up ecosystem for over 20 years, initially as an entrepreneur and then as an investor with SoftBank, NEC and DFJ ePlanet Capital. He has been a party to more than 120 investments across a broad range of sectors, stages and geographies.

At BGF Tim is responsible for identifying and executing investments, with a particular focus on tech-orientated propositions.

Outside of work Tim spends as much of his time as possible on horseback and, in the interest of combining work with pleasure, keeps a horse specifically for long conference calls. Tim has a science background and began his career in BT’s research labs developing materials for optical switching and amplification. He has an MBA from London Business School.

Juliet joined the OrganOx board in January 2021 as a Non-Executive Director, appointed on behalf of the University of Oxford and the Technikos Parties, and Chair of the Audit Committee. Juliet has spent over 20 years actively involved in the life sciences sector working as an investment banker and strategic adviser to healthcare companies in Europe. She headed up the European healthcare team at Stifel (formerly Oriel) and prior to this was a founding partner of Code Securities, a healthcare investment banking boutique which was acquired by Nomura, later forming Nomura Code. Juliet sits on the boards of public companies Vectura plc and Novacyt S.A. and chairs the Audit Committee of both companies.

George joined the OrganOx board in 2009, when the company spun-out from the University of Oxford. George is Founder of Oxford Investment Consultants and a Partner and co-Founder of Sloane Robinson LLP, an investment management business which invests in listed equities globally, with a particular focus on Asian and Emerging Markets.

George is an active investor in early stage technology and biotech companies with a particular focus on Oxford spinouts, and is a founding Partner of Technikos, a private equity partnership which invests in spinout companies from the Oxford Institute of Biomedical Engineering.

George is an honorary fellow of Keble College, Oxford where he graduated with a BA in Engineering Science, and is a former-member of Oxford University Endowment Management’s Investment Committee.

Dr. John Liddicoat joined the OrganOx board in December 2022 as a Non-Executive Director.

John is a healthcare executive with over 20 years of global healthcare experience. Most recently, John served on Medtronic's Executive Committee as Executive Vice President and President of the Medtronic Americas Region and Medtronic's Enterprise Technology and Innovation function. Known as a transformational leader focused on execution, John has centred his career on innovation-driven growth to improve healthcare around the world and drive shareholder value. He has taken products from concept through product development to global commercial launch.

Prior to joining Medtronic, John was a cardiac surgeon and Assistant Professor at Harvard Medical School, and served as a consultant to venture capital firms and early-stage medical device companies.

Samuel is a physician entrepreneur.

He started his career as a management consultant at McKinsey & Company in New York before moving to Boston to attend Harvard Medical School. As a second-year medical student, Samuel co-founded Allurion Technologies and built a fully-integrated, global medical device company from the idea stage to commercialization in more than 30 countries.

Samuel is a graduate of Yale College (summa cum laude) and Harvard Medical School. He was a Fulbright Scholar to France at the Pasteur Institute.